Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System

Min Kyoung Cho; Mira Moon; Hyun Hwa Kim; Dong Yoon Kang; Ju-Yeun Lee; Sang-Heon Cho; Hye-Ryun Kang

doi:10.4168/aard.2020.8.1.30

Journal List > Allergy Asthma Respir Dis > v.8(1) > 1141944

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Cho, Moon, Kim, Kang, Lee, Cho, and Kang: Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System

Original Article

Allergy, Asthma & Respiratory Disease 2020; 8(1): 30-35.

Published online: 31 January 2020

DOI: https://doi.org/10.4168/aard.2020.8.1.30

Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System

Min Kyoung Cho¹, Mira Moon¹, Hyun Hwa Kim¹, Dong Yoon Kang¹, Ju-Yeun Lee², Sang-Heon Cho^1,^3,⁴, Hye-Ryun Kang^1,^3,⁴

¹Drug Safety Monitoring Center, Seoul National University Hospital, Seoul, Korea.

²College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.

³Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea.

⁴Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Correspondence to: Hye-Ryun Kang. Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. Tel: +82-2-2072-0820, Fax: +82-2-742-3291, helenmed@snu.ac.kr

Received 18 June 2019 Revised 1 October 2019 Accepted 17 October 2019

The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Abstract

Purpose

To identify causative agents of the drug-induced anaphylaxis (DIA) by using the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System (KIDS-KAERS) database (Ministry of Food and Drug Safety) in Korea and to check their labeling information regarding anaphylaxis.

Methods

Among Individual Case Safety Reports from January, 2008 to December 2017, cases of DIA were analyzed for demographics, causative agents and fatal cases resulting in death. The domestic drug labeling, Micromedex and U.S. Food and Drug Administration (FDA) drug package insert, were reviewed to check if the labeling information on suspected causative agents contains anaphylaxis.

Results

A total of 4,700 cases of DIA were analyzed. The mean age was 49.85±18.32 years, and 2,642 patients (56.2%) were females. Among 8,664 drugs reported as causative agents, antibiotics (27.4%) accounted for the largest portion. There were 18 fatal cases: antibiotics (7 cases), antineoplastic agents (4 cases) were the major causative drugs for the mortality cases. Of 513 drugs reported as suspected causative agents, 103 (20.1%) did not list anaphylaxis as an adverse effect on domestic drug labeling and 16 (3.1%) did not reflect anaphylaxis in any of 3 adverse drug information.

Conclusion

Analysis of 10-year data showed that antibiotics were the main cause of DIA and the mortality rate was 0.7%. In 3.1% of suspected drugs, there was no description of anaphylaxis in any of the drug labeling.

Keywords: Drug-induced anaphylaxis, Pharmacovigilance, Drug labeling, Mortality rate

Figures and Tables

Fig. 1

The number of drug-induced anaphylaxis cases reported annually. ADR, adverse drug reaction.

Table 1

Demographic characteristics of patients with anaphylaxis (n=4,700)

Values are presented as number (%) or mean±standard deviation.

Table 2

Categories of causative agents of drug-induced anaphylaxis (n=6,212)

NSAID, nonsteroidal anti-inflammatory drug.

Table 3

Causal agents of drug-induced anaphylaxis

Table 4

Causative agents of the anaphylaxis-related deaths

NSAID, nonsteroidal anti-inflammatory drug.

Table 5

List of drugs which list anaphylaxis as an adverse drug reaction on FDA drug label but not on domestic drug label

FDA, U.S. Food and Drug Administration.

Table 6

List of drugs which did not list anaphylaxis as an adverse drug reaction on domestic drug label, FDA drug label, and Micromedex

FDA, U.S. Food and Drug Administration; 5-HT4, 5-hydroxytryptamine 4; HMG, 3-hydroxy-methyl glutaryl; CoA, Coenzyme A

Notes

This research was supported by a grant from Ministry of Food and Drug Safety to the regional pharmacovigilance center in 2019.

References

1. Bochner BS, Lichtenstein LM. Anaphylaxis. N Engl J Med. 1991; 324:1785–1790.

2. Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014; 133:461–467.

3. Jeong K, Lee JD, Kang DR, Lee S. A population-based epidemiological study of anaphylaxis using national big data in Korea: trends in age-specific prevalence and epinephrine use in 2010–2014. Allergy Asthma Clin Immunol. 2018; 14:31.

4. Zhao Y, Sun S, Li X, Ma X, Tang H, Sun L, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database. Int J Clin Pharm. 2018; 40:1349–1358.

5. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. Predictors of the severity and serious outcomes of anaphylaxis in korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015; 7:22–29.

6. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014; 134:1318–1328.

7. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, et al. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008; 100:31–36.

8. Moon IJ, Park HJ, Kim SR, Koh BS, Leem DW, Park KH, et al. Drug-induced anaphylaxis in a single Korean tertiary hospital. Korean J Med. 2015; 88:281–287.

9. Carneiro-Leão L, Barzylovych V, Cernadas J. Pemetrexed anaphylaxis-an unusual suspect. J Allergy Clin Immunol Pract. 2019; 7:320–321.

10. Yoo HS, Yang EM, Kim MA, Hwang SH, Shin YS, Ye YM, et al. A case of codeine induced anaphylaxis via oral route. Allergy Asthma Immunol Res. 2014; 6:95–97.

11. Donado CD, Díez EM. Successful desensitization for hydroxychloroquine anaphylaxis. J Rheumatol. 2010; 37:1975–1976.

12. Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, et al. Drug-induced anaphylaxis survey in Portuguese Allergy Departments. J Investig Allergol Clin Immunol. 2014; 24:40–48.

13. Korea Institute of Drug Safety & Risk Management. 2018 Drug safety information report. Anyang (Korea): Korea Institute of Drug Safety & Risk Management;2018.

14. Ku JH, Kang PS, Cho CK, Jung SM, Lim YS, Kim SH, et al. Anaphylaxis induced by intravenous ranitidine injection: 2 case reports. Korean J Crit Care Med. 2010; 25:253–256.

15. Chopra D, Arora P, Khan S, Dwivedi S. Anaphylaxis following intravenous ranitidine: a rare adverse reaction of a common drug. Indian J Pharmacol. 2014; 46:234–236.

16. Park KH, Pai J, Song DG, Sim DW, Park HJ, Lee JH, et al. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing. Clin Exp Allergy. 2016; 46:631–639.

17. Kim H, Fischer D. Anaphylaxis. Allergy Asthma Clin Immunol. 2011; 7 Suppl 1:S6.

TOOLS

ORCID iDs: Hye-Ryun Kang
https://orcid.org/0000-0002-2317-4201
Similar articles